Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

By William Pao, Vincent A. Miller. Journal of Clinical Oncology, 2005

621 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Nanomedicine therapeutic approaches to overcome cancer drug resistance (2013, background): “Nearly 70% of patients with a mutation (found in 10-25% of all NSCLC patients) respond to therapy compared to only a 10% response rate when no mutations are present [55,56].”
Molecular Epidemiology of EGFR and KRAS Mutations in 3026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-related KRAS-mutant Cancers (2012, background): “More than 90% of EGFR mutations are small in frame deletions in exon 19 and L858R missense mutation in exon 21.(1) These mutations are associated with responsiveness to tyrosine kinase inhibitors (TKI) therapy.”